What is the clinical evidence from this study?

Study design: Cohort. Population: High bleeding risk undergoing percutaneous coronary intervention (n=3364). Intervention: 1-month dual antiplatelet therapy vs. 3-month dual antiplatelet therapy. Primary outcome: all-cause death or myocardial infarction (adjHR 0.94, 95% CI 0.59-1.52, p=0.807).

What question did this study set out to answer?

This analysis aims to determine the impact of dual antiplatelet therapy duration on ischemic and bleeding outcomes in high bleeding risk patients with baseline anemia.

July 26, 2026Open Access

Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention.

View Full Paper

Ask AI

Bookmark

Why the study?

Although abbreviated DAPT reduces bleeding without increasing ischemic risk in HBR patients undergoing PCI, the optimal duration in specific subgroups like anemic patients remains unclear.

Does 1-month DAPT reduce bleeding without increasing ischemic risk compared to 3-month DAPT in high bleeding risk patients with baseline anemia undergoing PCI?

Population

3,364 HBR patients undergoing PCI with cobalt-chromium everolimus-eluting stents

Comparison

1-month DAPT vs 3-month DAPT stratified by anemia status

Design

Propensity score-stratified analysis of three prospective trials

Follow-up

1 year

Key result

In anemic high bleeding risk patients undergoing PCI, 1-month DAPT had similar ischemic outcomes (HR 0.94; 95% CI 0.59-1.52) but lower major bleeding (HR 0.49) compared to 3-month DAPT.

Authors

FMFrancesca Maria Di Muro SSSamantha Sartori DADominick J Angiolillo

Discussion

Member takes

Overview

Anemia marks higher ischemic and bleeding risk after short DAPT in HBR PCI patients; extends XIENCE program data to this subgroup.

Key Points

This analysis aims to determine the impact of dual antiplatelet therapy duration on ischemic and bleeding outcomes in high bleeding risk patients with baseline anemia.
Included 3,364 high bleeding risk patients from three trials in the XIENCE Short DAPT Program
Defined anemia as hemoglobin <11 g/dL and assessed outcomes using propensity score stratification
Primary endpoint was all-cause death or myocardial infarction; secondary endpoints included BARC 2-5 and 3-5 bleeding.
Anemic patients had higher rates of ischemic and bleeding events at 1 year compared to non-anemic patients.
1-month DAPT in anemic patients had a major bleeding incidence of 6.1% vs 11.1% for 3-month DAPT (adjHR 0.49, 95% CI 0.24-1.00; p=0.050) with similar ischemic outcomes.
In non-anemic patients, outcomes were similar regardless of DAPT duration.

Study Design

Type

Cohort (n=3,364)

Multicenter

Yes

Structured PICO

Does 1-month DAPT reduce bleeding without increasing ischemic risk compared to 3-month DAPT in high bleeding risk patients with baseline anemia undergoing PCI?

Population

3,364 high bleeding risk patients undergoing percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents, followed for 1 year.

Exposure

1-month dual antiplatelet therapy (DAPT)

Comparator

3-month dual antiplatelet therapy (DAPT)

Outcome

Composite of all-cause death or myocardial infarction at 1 yearcomposite

Main Result

Hazard Ratio: 0.94 (95% CI 0.59–1.52)

Absolute Event Rate: 15.7% vs 16.3%

p-value: p=0.807

In high bleeding risk patients with baseline anemia undergoing PCI, abbreviating DAPT to 1 month reduces major bleeding without increasing ischemic risk compared to 3 months of DAPT.

Limitations

Results should be interpreted with caution and confirmed in randomized studies
Non-randomized comparison (propensity score stratified) requiring confirmation in randomized studies

Cite This Study

Muro et al. (2026) conducted a cohort in High bleeding risk undergoing percutaneous coronary intervention (n=3,364). 1-month dual antiplatelet therapy vs. 3-month dual antiplatelet therapy was evaluated on all-cause death or myocardial infarction (adjHR 0.94, 95% CI 0.59-1.52, p=0.807). In anemic high bleeding risk patients undergoing PCI, 1-month DAPT had similar ischemic outcomes (HR 0.94; 95% CI 0.59-1.52) but lower major bleeding (HR 0.49) compared to 3-month DAPT.

synapsesocial.com/papers/6a65a7e0d3aea3239cd7876c https://doi.org/10.48620/99769

View Full Paper

Ask AI

Bookmark

July 26, 2026Open Access

Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention.

View Full Paper

Ask AI

Bookmark

Why the study?

Although abbreviated DAPT reduces bleeding without increasing ischemic risk in HBR patients undergoing PCI, the optimal duration in specific subgroups like anemic patients remains unclear.

Does 1-month DAPT reduce bleeding without increasing ischemic risk compared to 3-month DAPT in high bleeding risk patients with baseline anemia undergoing PCI?

Population

3,364 HBR patients undergoing PCI with cobalt-chromium everolimus-eluting stents

Comparison

1-month DAPT vs 3-month DAPT stratified by anemia status

Design

Propensity score-stratified analysis of three prospective trials

Follow-up

1 year

Key result

In anemic high bleeding risk patients undergoing PCI, 1-month DAPT had similar ischemic outcomes (HR 0.94; 95% CI 0.59-1.52) but lower major bleeding (HR 0.49) compared to 3-month DAPT.

Authors

FMFrancesca Maria Di Muro SSSamantha Sartori DADominick J Angiolillo

Discussion

Member takes

Overview

Anemia marks higher ischemic and bleeding risk after short DAPT in HBR PCI patients; extends XIENCE program data to this subgroup.

Key Points

This analysis aims to determine the impact of dual antiplatelet therapy duration on ischemic and bleeding outcomes in high bleeding risk patients with baseline anemia.
Included 3,364 high bleeding risk patients from three trials in the XIENCE Short DAPT Program
Defined anemia as hemoglobin <11 g/dL and assessed outcomes using propensity score stratification
Primary endpoint was all-cause death or myocardial infarction; secondary endpoints included BARC 2-5 and 3-5 bleeding.
Anemic patients had higher rates of ischemic and bleeding events at 1 year compared to non-anemic patients.
1-month DAPT in anemic patients had a major bleeding incidence of 6.1% vs 11.1% for 3-month DAPT (adjHR 0.49, 95% CI 0.24-1.00; p=0.050) with similar ischemic outcomes.
In non-anemic patients, outcomes were similar regardless of DAPT duration.

Study Design

Type

Cohort (n=3,364)

Multicenter

Yes

Structured PICO

Does 1-month DAPT reduce bleeding without increasing ischemic risk compared to 3-month DAPT in high bleeding risk patients with baseline anemia undergoing PCI?

Population

3,364 high bleeding risk patients undergoing percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents, followed for 1 year.

Exposure

1-month dual antiplatelet therapy (DAPT)

Comparator

3-month dual antiplatelet therapy (DAPT)

Outcome

Composite of all-cause death or myocardial infarction at 1 yearcomposite

Main Result

Hazard Ratio: 0.94 (95% CI 0.59–1.52)

Absolute Event Rate: 15.7% vs 16.3%

p-value: p=0.807

In high bleeding risk patients with baseline anemia undergoing PCI, abbreviating DAPT to 1 month reduces major bleeding without increasing ischemic risk compared to 3 months of DAPT.

Limitations

Results should be interpreted with caution and confirmed in randomized studies
Non-randomized comparison (propensity score stratified) requiring confirmation in randomized studies

Cite This Study

synapsesocial.com/papers/6a65a7e0d3aea3239cd7876c https://doi.org/10.48620/99769

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark